CompletedPhase 1NCT02541565

Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

Studying Composite lymphoma

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of Washington
Principal Investigator: Stephen Smith
Fred Hutch/University of Washington Cancer Consortium
Intervention: Cyclophosphamide(drug)
Enrollment: 30 enrolled
Eligibility: 18 years · All sexes
Timeline: 2015 – 2018

Study locations (1)

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02541565 on ClinicalTrials.gov

Other trials for Composite lymphoma

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05025800
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center

See all trials for Composite lymphoma →

← Back to all trials